Literature DB >> 35707591

Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease.

Mehmet Akif Ovali1, Ibrahim Bozgeyik2.   

Abstract

Background: Asprosin is a novel fasting-induced, glucogenic, and orexigenic protein hormone that is discovered with the help of genetic studies in patients with neonatal progeroid syndrome. Asprosin is encoded by the penultimate 2 exons (65 and 66) of the fibrillin 1 (FBN1) gene. Profibrillin 1 is the unprocessed protein product of FBN1 and undergoes a proteolytic cleavage by furin enzyme to produce mature fibrillin 1 and asprosin. The main organ responsible for the asprosin production seems to be white adipose tissue. Summary: Asprosin promotes hepatic glucose release in the liver and appetite stimulation in the hypothalamus through activation of the cAMP signaling circuitry through interacting with its G protein-coupled receptor, called OR4M1. Increasing mass of evidence suggests that asprosin is involved in the development and progression of various clinical conditions including diabetes, obesity, cardiomyopathy, cancer, and polycystic ovarian syndrome. It regulates various cellular and physiological processes such as appetite stimulation, glucose release, insulin secretion, apoptotic cell death, and inflammatory response. In this review, we discuss the current literature on asprosin and try to shed light on the yet undiscovered functions of asprosin. Key Message: Asprosin is a key regulatory factor for preserving the homeostasis of energy metabolism.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Asprosin; FBN1; Fibrillin 1; Marfan syndrome; Neonatal progeroid syndrome

Year:  2022        PMID: 35707591      PMCID: PMC9149429          DOI: 10.1159/000520333

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  59 in total

1.  Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway.

Authors:  Zhengbin Zhang; Yanzhen Tan; Liwen Zhu; Bing Zhang; Pan Feng; Erhe Gao; Chennian Xu; Xiaoming Wang; Wei Yi; Yang Sun
Journal:  Life Sci       Date:  2019-06-10       Impact factor: 5.037

2.  Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?

Authors:  N Kocaman; G Artaş
Journal:  Biotech Histochem       Date:  2019-10-01       Impact factor: 1.718

3.  Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin.

Authors:  Nevzat Gozel; Faruk Kilinc
Journal:  Endokrynol Pol       Date:  2020-09-18       Impact factor: 1.582

4.  Asprosin, a Fasting-Induced Glucogenic Protein Hormone.

Authors:  Chase Romere; Clemens Duerrschmid; Juan Bournat; Petra Constable; Mahim Jain; Fan Xia; Pradip K Saha; Maria Del Solar; Bokai Zhu; Brian York; Poonam Sarkar; David A Rendon; M Waleed Gaber; Scott A LeMaire; Joseph S Coselli; Dianna M Milewicz; V Reid Sutton; Nancy F Butte; David D Moore; Atul R Chopra
Journal:  Cell       Date:  2016-04-14       Impact factor: 41.582

5.  Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome.

Authors:  Murat Alan; Beril Gurlek; Alpay Yilmaz; Murat Aksit; Behnaz Aslanipour; Ibrahim Gulhan; Calan Mehmet; Cuneyt Eftal Taner
Journal:  Gynecol Endocrinol       Date:  2018-10-16       Impact factor: 2.260

6.  Saliva and Blood Asprosin Hormone Concentration Associated with Obesity.

Authors:  Kader Ugur; Suleyman Aydin
Journal:  Int J Endocrinol       Date:  2019-03-27       Impact factor: 3.257

7.  CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.

Authors:  Kalliopi G Gkouskou; Georgios Georgiopoulos; Ioannis Vlastos; Evgenia Lazou; Dimitrios Chaniotis; Theodore G Papaioannou; Christos S Mantzoros; Despina Sanoudou; Aristides G Eliopoulos
Journal:  Int J Obes (Lond)       Date:  2021-09-25       Impact factor: 5.095

8.  Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes.

Authors:  Jan Benedikt Groener; Aikaterini Valkanou; Zoltan Kender; Jan Pfeiffenberger; Lars Kihm; Thomas Fleming; Peter Paul Nawroth; Stefan Kopf
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

9.  High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome.

Authors:  Tao Hong; Jiao-Yang Li; Ya-Di Wang; Xiao-Yan Qi; Zhe-Zhen Liao; Poonam Bhadel; Li Ran; Jing Yang; Bin Yan; Jiang-Hua Liu; Xin-Hua Xiao
Journal:  Int J Endocrinol       Date:  2021-03-02       Impact factor: 3.257

10.  Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice.

Authors:  Haiming Ma; Guina Zhang; Chunrong Mou; Xiujuan Fu; Yadan Chen
Journal:  Front Pharmacol       Date:  2018-03-20       Impact factor: 5.810

View more
  1 in total

1.  Overexpression and ELISA-based detection of asprosin in cultured cells and mice.

Authors:  Ila Mishra; Atul R Chopra
Journal:  STAR Protoc       Date:  2022-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.